
|Articles|June 10, 2019
Neuroprotective implant for treatment of glaucoma in phase II trial
Author(s)Julianne Mobilian
Here's the latest innovations at Neurotech Pharmaceuticals, Inc.
Advertisement
Rich Small, CPA, CEO of
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron receives another CRL for its Eylea 8 mg
2
Eli Lilly to acquire Adverum Biotechnologies
3
Anti-VEGF innovations in retinal disease: From molecules to medicine
4
Topcon Healthcare seeks to advance company through acquisition and new investment
5


















































.png)


